The selection of the solid form of an API has a significant
effect on product performance. Polymorphs, hydrates, and
salts are the commonly available options if a crystalline form
is desired. Cocrystals present an additional option, and a
very significant one if the API is non-ionizable or unable to
form effective salts.
If the unique cocrystal properties can be leveraged to create
the basis of a drug formulation that cannot be duplicated
without the use of the cocrystal, the cocrystal patent will
preserve market exclusivity beyond the expiration of the
molecule patent or any FDA exclusivity.
Renovo's cocrystal screening technology is used to identify
and establish new IP for new cocrystals of an API.
The improved cocrystal properties are used to develop a drug
delivery mechanism that will create the product improvement.
Research by Renovo and for Renovo partners has resulted in
a portfolio of cocrystal technology that is available for
The primary focus in most cocrystal projects
is improving the solubility of a poorly soluble
API. Especially for non-ionizable APIs or
APIs that do not form salts, cocrystals
represent a significant opportunity to identify
crystalline forms with dramatically improved
solubility and dissolution rate.
In addition to improving solubility, cocrystals
can be used to reduce hygroscopicity,
generate crystalline forms of non-crystalline
materials, purify or resolve an API, or
stabilize unstable molecules.
In situations that require amorphous,
lyophylized, spray-dried, micro or
nano-sized particles or similar extreme
processing conditions, cocrystals may
provide the required properties in a
crystalline form that can perform as well or
better without any additional processing.
2011 Renovo Research, LLC. All rights reserved.
Cocrystals can create
cocrystals of pharmaceuticals...